文献速递银屑病与炎症性皮肤病

血清乌司奴单抗水平与银屑病临床应答的关联

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis.
PubMed 文献 · JAMA Dermatol · 2019-01-01

该前瞻性观察队列纳入491例银屑病患者,测量血清乌司奴单抗水平并评估PASI应答。早期(1-12周)药物水平与6个月时PASI75应答相关(OR 1.38,95%CI 1.11-1.71),但与其他PASI结局不一致。提示早期药物暴露可能指导治疗策略。

要点

  • 早期血清乌司奴单抗水平与6个月PASI75应答独立相关。
  • 该关联未在PASI90和绝对PASI≤1.5中一致重现。
  • 抗药抗体阳性率低(17/490,3.5%)。

核心结论

  • 真实世界研究提示早期血清乌司奴单抗水平测量可能有助于指导银屑病治疗策略。

研究设计与样本

  • 前瞻性观察队列研究,纳入491例成人银屑病患者,来自英国皮肤科医师协会生物制剂和免疫调节剂登记处的多中心研究。

主要发现

  • 早期(治疗开始后1-12周)测得药物水平与治疗6个月时PASI75应答相关(OR 1.38;95%CI 1.11-1.71),校正基线PASI评分、年龄和乌司奴单抗剂量。
  • 该关联在PASI90和绝对PASI≤1.5结局中不一致。
  • 490例患者中仅17例(3.5%)检测到抗药抗体。

关键数值与推荐

  • PASI75定义为PASI评分较基线下降75%,为主要结局。
  • PASI90定义为PASI评分较基线下降90%。
  • 绝对PASI评分≤1.5为另一结局。

临床怎么用

  • 可考虑在治疗早期(1-12周)监测血清乌司奴单抗水平,以识别PASI75应答可能不佳者并调整策略。

局限性

  • 早期药物水平与PASI75的关联未在其他PASI结局中一致重现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: High-cost biologic therapies have transformed the management of immune-mediated inflammatory diseases. To optimize outcomes and reduce costs, dose adjustment informed by measurement of circulating drug levels has been shown to be effective in various settings. However, limited evidence exists for this approach with the interleukin 12 and interleukin 23 inhibitor ustekinumab. OBJECTIVE: To evaluate clinical utility of therapeutic drug monitoring for ustekinumab in patients with psoriasis. DESIGN, SETTING, AND PARTICIPANTS: A prospective observational cohort of 491 adults with psoriasis was recruited to the multicenter Biomarkers of Systemic Treatment Outcomes in Psoriasis study within the British Association of Dermatologists Biologic and Immunomodulators Register from June 2009 to December 2017; samples from some patients were taken between 2009 and 2011 as part of a pilot study with the same inclusion criteria. EXPOSURE: Serum ustekinumab level measured at any point during the dosing cycle using an enzyme-linked immunosorbent assay. MAIN OUTCOMES AND MEASURES: Disease activity measured using the Psoriasis Area and Severity Index (PASI) score. Treatment response outcomes were PASI75 (75% reduction in PASI score from baseline [primary outcome]), PASI90 (90% reduction of PASI score from baseline), and absolute PASI score of 1.5 or less. RESULTS: A total of 491 patients (171 women and 320 men; mean [SD] age, 45.7 [12.8] years) had 1 or more serum samples (total, 853 samples obtained 0-56 weeks from start of treatment) and 1 or more PASI scores within the first year of treatment. Antidrug antibodies were detected in only 17 of 490 patients (3.5%). Early measured drug levels (1-12 weeks after starting treatment) were associated with PASI75 response 6 months after starting treatment (odds ratio, 1.38; 95% CI, 1.11-1.71) when adjusted for baseline PASI score, age, and ustekinumab dose. However, this finding was not consistent across the other PASI outcomes (PASI90 and PASI score of ≤1.5). CONCLUSIONS AND RELEVANCE: This real-world study provides evidence that measurement of early serum ustekinumab levels could be useful to direct the treatment strategy for psoriasis. Adequate drug exposure early in the treatment cycle may be particularly important in determining clinical outcome.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Tsakok T, Wilson N, Dand N, et al. Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. JAMA Dermatol. 2019. PMID: 31532460. doi:10.1001/jamadermatol.2019.1783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。